- Neo-POLEM
Trial Status
In follow-up
Cancer Type
Colorectal Cancer
Protocol Title
A phase II trial of neoadjuvant PD-1 vaccine (PD1-Vaxx) in operable MSI high colorectal cancer.
Purpose of the Study
Early stage colon cancer that has spread to the local lymph nodes is best treated with surgery and chemotherapy, however, half of patients treated will have subsequent recurrence of their cancer. If this happens the cancer is often incurable.
About 1 in 7 colon cancer have ‘defective mismatch repair’ and recent small trials of immunotherapy drugs appear to work exceptionally well in this subtype of cancer. In Neo-POLEM we will use a vaccine approach that is hoped to have a durable effect. The vaccine, PD1-Vaxx, is designed to work by stimulating the immune system to attach the patient’s cancer and it’s predicted that this subtype of cancer may be particularly sensitive to this approach.
Neo-POLEM aims to recruit a maximum of 44 patients in total, 24 in the UK and 20 in Australia. Participants in the study will receive 3 vaccinations, once every 2 weeks over a 6 week period. Following treatment patients will undergo standard care surgery and following this will be followed up for a maximum of two years.
Contact Email
DETAILED INFORMATION AVAILABLE
More detailed information available online at ClinicalTrials.gov please click here, and at the Australian New Zealand Clinical Trial Registry, please click here.
Study Chairs
Professor Tim Price
Dr Tharani Krishnan
Funding
Imugene Limited
Trial Status
In follow-up
Cancer Type
Colorectal Cancer
